Actively Recruiting
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Led by Nuwacell Biotechnologies Co., Ltd. · Updated on 2025-08-01
48
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
CONDITIONS
Official Title
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages between 40 and 75 years
- Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria
- Disease history over 5 years
- Stable dose of dopamine treatment
- Able to undergo PET/CT/MRI detection
You will not qualify if you...
- Patients who have previously undergone brain surgery
- Past use of stem cell therapy or participation in stem cell clinical research
- Cognitive impairment
- History of mental disorders
- Patients with other serious systemic diseases
- Past or current metastatic malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of USTC
Hefei, Anhui, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here